Land: Armenien
Sprog: engelsk
Kilde: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
insulin human
Novo Nordisk A/S
A10AB01
insulin human
100IU/ml
solution for injection
(5) glass cartridges 3ml
Prescription
Registered
2019-02-12
Regulatory Operations Insert: 2010-501,65x150-001 Current 5 Professionel COLOUR: PMS 280C Actrapid® Penfill® 100 IU/ml Solution for injection in cartridge. QUALITATIVE AND QUANTITATIVE COMPOSITION Insulin human, rDNA (produced by recombinant DNA technology in _Saccharomyces cerevisiae_). 1 ml contains 100 IU of insulin human. 1 cartridge contains 3 ml equivalent to 300 IU. One IU (International Unit) corresponds to 0.035 mg of anhydrous human insulin. PHARMACEUTICAL FORM Solution for injection in cartridge. Clear, colourless, aqueous solution. THERAPEUTIC INDICATIONS Treatment of diabetes mellitus. POSOLOGY AND METHOD OF ADMINISTRATION Actrapid® is a fast-acting insulin and may be used in combination with long-acting insulin products. DOSAGE Dosage is individual and determined in accordance with the needs of the patient. The individual insulin requirement is usually between 0.3 and 1.0 IU/kg/day. The daily insulin requirement may be higher in patients with insulin resistance (e.g. during puberty or due to obesity) and lower in patients with residual, endogenous insulin production. An injection should be followed within 30 minutes by a meal or snack containing carbohydrates. DOSAGE ADJUSTMENT Concomitant illness, especially infections and feverish conditions, usually increases the patient’s insulin requirement. Concomitant diseases in the kidney, liver or affecting the adrenal, pituitary or thyroid gland can require changes in the insulin dose. Adjustment of dosage may also be necessary if patients change physical activity or their usual diet. Dosage adjustment may be necessary when transferring patients from one insulin preparation to another. ADMINISTRATION For subcutaneous or intravenous use. Actrapid® is administered subcutaneously in the abdominal wall. If convenient, the thigh, the gluteal region or the deltoid region may also be used. Subcutaneous injection into the abdominal wall ensures a faster absorption than from other injection sites. Injection into a lifted skin fold minimises the risk of unint Læs hele dokumentet